Bull Harbor Capital LLC Purchases Shares of 5,955 Edwards Lifesciences Corporation $EW

Bull Harbor Capital LLC purchased a new stake in Edwards Lifesciences Corporation (NYSE:EW) during the first quarter, according to its most recent 13F filing with the SEC. The firm purchased 5,955 shares of the medical research company’s stock, valued at approximately $477,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Hanson & Doremus Investment Management bought a new position in shares of Edwards Lifesciences during the 1st quarter worth approximately $25,000. JPL Wealth Management LLC purchased a new stake in Edwards Lifesciences during the third quarter valued at approximately $25,000. MV Capital Management Inc. acquired a new stake in Edwards Lifesciences in the fourth quarter valued at approximately $26,000. RMG Wealth Management LLC acquired a new stake in Edwards Lifesciences in the first quarter valued at approximately $26,000. Finally, Kemnay Advisory Services Inc. purchased a new position in Edwards Lifesciences in the fourth quarter worth $27,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Trading Down 0.9%

Shares of Edwards Lifesciences stock opened at $86.17 on Friday. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 12-month low of $72.30 and a 12-month high of $96.29. The firm has a market capitalization of $49.62 billion, a price-to-earnings ratio of 49.52, a PEG ratio of 2.18 and a beta of 0.86. The firm’s 50 day simple moving average is $87.91 and its two-hundred day simple moving average is $83.89.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.85%. The business had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.70 billion. During the same quarter last year, the company posted $0.67 earnings per share. The business’s quarterly revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, SVP Andrew M. Dahl sold 568 shares of the business’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the sale, the senior vice president owned 15,334 shares in the company, valued at approximately $1,319,950.72. The trade was a 3.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 1,019 shares of the business’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $83.98, for a total value of $85,575.62. Following the sale, the vice president owned 33,682 shares in the company, valued at approximately $2,828,614.36. The trade was a 2.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 44,558 shares of company stock valued at $3,770,939 in the last ninety days. Company insiders own 0.31% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. Piper Sandler reaffirmed an “overweight” rating and set a $101.00 price target (up from $100.00) on shares of Edwards Lifesciences in a research report on Friday, July 24th. UBS Group assumed coverage on Edwards Lifesciences in a research report on Tuesday. They issued a “buy” rating and a $110.00 price objective for the company. Citigroup boosted their target price on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Truist Financial upped their target price on Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a research report on Thursday, July 16th. Finally, Barclays reiterated an “overweight” rating and issued a $110.00 price target (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. Seventeen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $100.27.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.